A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

So Lilly isn't dependent on just one or two products, and that's positive ... first gave it the nod for type 2 diabetes in 2022 then approved it specifically for weight loss in 2023.

Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) which offer obesity/ diabetes drugs, tirzepatide and semaglutide will be competing neck and neck in the GLP-1 market in 2030 with their products ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs ... some compounded products aren’t FDA ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

(The Hill) – A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro.

In a statement, Ricks also said the investment reflects the company’s “optimism” about its ability to develop pipeline products ... knockoff versions of Lilly’s diabetes and obesity ...